Nucala®
Mepolizumab is an anti-IL-5 monoclonal antibody for severe eosinophilic asthma. It reduces blood eosinophils and asthma exacerbations.
| Dosage Form | SC Injectable (Lyophilized Powder / Prefilled Syringe / Autoinjector) |
| Strength | 100 mg/mL |
| Storage | Store at 2–8°C. Do not freeze. Protect from light. |
| Category | Respiratory |
| Availability | Available for Transfer |
Severe asthma with eosinophilic phenotype (add-on maintenance, ≥6 years); eosinophilic granulomatosis with polyangiitis (EGPA); hypereosinophilic syndrome (HES).
Humanized IgG1 monoclonal antibody that binds to IL-5, preventing it from binding to the IL-5 receptor alpha on eosinophil surfaces. This reduces eosinophil production, maturation, and survival.
Each Burrard Pharmaceuticals technology transfer package for Mepolizumab includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.